tbuckley/cabot-search huggingface dataset:
STRIKES IN HOSPITALS
Authors: W A Rothman
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Apoptosis: A Factor in Neoplastic Growth?
Authors: Z Danilevicius
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Characteristics and Outcomes of Patients Presenting With Hypertensive Urgency in the Office Setting
Authors: Krishna K. Patel, Laura Young, Erik H. Howell, Bo Hu, Gregory Rutecki, George Thomas, Michael B. Rothberg
Journal: JAMA Internal Medicine (2016)

The prevalence and short-term outcomes of hypertensive urgency (systolic blood pressure ≥180 mm Hg and/or diastolic blood pressure ≥110 mm Hg) are unknown. Guidelines recommend achieving blood pressure control within 24 to 48 hours. However, some patients are referred to the emergency department (ED) or directly admitted to the hospital, and whether hospital management is associated with better outcomes is unknown.To describe the prevalence of hypertensive urgency and the characteristics and short-term outcomes of these patients, and to determine whether referral to the hospital is associated with better outcomes than outpatient management.This retrospective cohort study with propensity matching included all patients presenting with hypertensive urgency to an office in the Cleveland Clinic Healthcare system from January 1, 2008, to December 31, 2013. Pregnant women and patients referred to the hospital for symptoms or treatment of other conditions were excluded. Final follow-up was completed on June 30, 2014, and data were assessed from October 31, 2014, to May 31, 2015.Hospital vs ambulatory blood pressure management.Major adverse cardiovascular events (MACE) consisting of acute coronary syndrome and stroke or transient ischemic attack, uncontrolled hypertension (≥140/90 mm Hg), and hospital admissions.Of 2 199 019 unique patient office visits, 59 836 (4.6%) met the definition of hypertensive urgency. After excluding 851 patients, 58 535 were included. Mean (SD) age was 63.1 (15.4) years; 57.7% were women; and 76.0% were white. Mean (SD) body mass index (calculated as weight in kilograms divided by height in meters squared) was 31.1 (7.6); mean (SD) systolic blood pressure, 182.5 (16.6) mm Hg; and mean (SD) diastolic blood pressure, 96.4 (15.8) mm Hg. In the propensity-matched analysis, the 852 patients sent home were compared with the 426 patients referred to the hospital, with no significant difference in MACE at 7 days (0 vs 2 [0.5%]; P = .11), 8 to 30 days (0 vs 2 [0.5%]; P = .11), or 6 months (8 [0.9%] vs 4 [0.9%]; P > .99). Patients sent home were more likely to have uncontrolled hypertension at 1 month (735 of 852 [86.3%] vs 349 of 426 [81.9%]; P = .04) but not at 6 months (393 of 608 [64.6%] vs 213 of 320 [66.6%]; P = .56). Patients sent home had lower hospital admission rates at 7 days (40 [4.7%] vs 35 [8.2%]; P = .01) and at 8 to 30 days (59 [6.9%] vs 48 [11.3%]; P = .009).Hypertensive urgency is common, but the rate of MACE in asymptomatic patients is very low. Visits to the ED were associated with more hospitalizations, but not improved outcomes. Most patients still had uncontrolled hypertension 6 months later.
The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy
Authors: Jeong Han Kim, Sung Hyun Ahn, Soon Young Ko, Won Hyeok Choe, Kyun-Hwan Kim, So Young Kwon
Journal: Clinical and Molecular Hepatology (2016)

See the commentary-article "Is the tenofovir based therapy almighty for previous treatment failure in chronic hepatitis B?" on page 238.
Inflammation of the Bladder and Urinary Fever.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Virus of Avian Erythromyeloblastic Leukosis. VI. Properties of the Enzyme Associated with the Virus in Dephosphorylating Adenosine Triphosphate&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;
Authors: Irving Green, J. W. Beard
Journal: JNCI Journal of the National Cancer Institute (1955)

Journal Article Virus of Avian Erythromyeloblastic Leukosis. VI. Properties of the Enzyme Associated with the Virus in Dephosphorylating Adenosine Triphosphate Get access Irving Green, Irving Green Department of Surgery, Duke University School of Medicine, Durham, N. C. Search for other works by this author on: Oxford Academic PubMed Google Scholar J. W. Beard J. W. Beard Department of Surgery, Duke University School of Medicine, Durham, N. C. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 15, Issue 5, April 1955, Pages 1217–1229, https://doi.org/10.1093/jnci/15.5.1217 Published: 01 April 1955 Article history Received: 13 September 1954 Published: 01 April 1955
Treatment-related ototoxicity.
Authors: D A Walker, K D Waters
Journal: Journal of Clinical Oncology (1990)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1990.8.1.179 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2295908 Treatment-related ototoxicity. D A WalkerxD A WalkerSearch for articles by this author , K D WatersxK D WatersSearch for articles by this author https://doi.org/10.1200/JCO.1990.8.1.179 PDF "Treatment-related ototoxicity.." Journal of Clinical Oncology, 8(1), pp. 179–180© 1990 by American Society of Clinical Oncology
NS-18ROLE OF METFORMIN IN THE TREATMENT OF HYPOTHALAMIC OBESITY SYNDROME (HOS)
Authors: Arundoss Gangadharan, Aliki Bogiatzopoulou, Joanne Blair, Barry Pizer, Lisa Howell, James Hayden, Conor Mallucci, Benedetta Pettorini, Mohammed Didi
Journal: Neuro-Oncology (2016)

NS-18. ROLE OF METFORMIN IN THE TREATMENT OF HYPOTHALAMIC OBESITY SYNDROME (HOS) Arundoss Gangadharan1, Aliki Bogiatzopoulou1, Joanne Blair1, Barry Pizer2, Lisa Howell2, James Hayden2, Conor Mallucci3, Benedetta Pettorini3, and Mohammed Didi1; Department of Endocrinology, Alder Hey Children’s Hospital, Liverpool, UK; Department of Oncology, Alder Hey Children’s Hospital,Liverpool, UK; Department of Neurosurgery,Alder HeyChildren’s Hospital, Liverpool, UK BACKGROUND: HOS in children with structural hypothalamic lesions is characterised by weight gain refractory to standard lifestyle interventions. Disruption of hypothalamic function results in hyperphagia, hyperinsulinemia and possible reduction of energy expenditure. Metformin induces anorectic effects, but its role in these patients has not been studied. OBJECTIVE: To compare BMI of patients with HOS before and after treatment with Metformin. METHOD: BMI of 6 children with HOS unresponsive to demonstrable change in lifestyle measures was compared before and after treatment with metformin by converting BMI to BMI standard deviation scores (SDS). Tolerance to metformin was assessed. RESULTS: There were 6 females. [Hypothalamic hamartoma (N 1⁄4 2), craniopharyngioma (N 1⁄4 2), hypothalamic astrocytoma (N 1⁄4 2)]. Treatment included surgery (N 1⁄4 5), primary fractionated radiotherapy (N 1⁄4 1), additional proton beam radiotherapy (N 1⁄4 1) and chemotherapy (N 1⁄4 1). Results are given as median (range). Age at diagnosis was 10.1years (1.3-13.8). Metformin was introduced at 12.5years of age (4.5-18.1). The change in BMI SDS was +0.42/year (+0.06 to +3.6) after 4.3 years (0.2 to 7.1). The change in BMI SDS between commencement of metformin and the final assessment was +0.15/ year (-0.31 to +0.22) after follow up of 1.9 years (1.3-5.4). The rate of change in BMI SDS before and after introduction of metformin is statistically significant (p1⁄4 0.043). CONCLUSION: Use of metformin in addition to lifestyle change is associated with control of obesity in patients with HOS and structural disease where lifestyle change alone was not successful. A prospective study is warranted to rigorously examine its role in this difficult group of patients. Neuro-Oncology 18:iii127–iii134, 2016. doi:10.1093/neuonc/now078.18 #The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Sideswipe injury to right elbow
Authors: O. E. Aufranc
Journal: JAMA (1964)

Dr. C. B. Sledge: A 17-year-old boy sustained a sideswipe injury to his right elbow in an automobile accident. He was sitting on the right side of the front seat with his right elbow resting on the door and protruding through the window space when the accident occurred. He sustained severe lacerations of the right arm and forearm with an avulsion of approximately 7 inches of the distal shaft of the humerus (Fig 1) and fractures of both bones of the right forearm (Fig 2). Both humeral condyles were present, but there was an intercondylar fracture. He also sustained a fracture of the right carpal navicular (Fig 1,<i>right</i>). Circulation in the hand was intact. Initial treatment consisted of debridement and partial closure of the wound with the application of skeletal traction through the olecranon. The patient was given tetanus toxoid and antibiotics. However, a wound infection developed on the
Quantitative Histochemical Observations on Butter-Yellow Carcinogenesis&lt;xref ref-type="fn" rid="fn1"&gt;1&lt;/xref&gt;, &lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;, &lt;xref ref-type="fn" rid="fn3"&gt;3&lt;/xref&gt;
Authors: Scott, Jesse F., Taft, Edgar B.
Journal: JNCI Journal of the National Cancer Institute (1955)

Journal Article Quantitative Histochemical Observations on Butter-Yellow Carcinogenesis, , Get access Jesse F. Scott, M.D., Jesse F. Scott, M.D. The Medical Laboratories of the Collis P. Huntington Memorial Hospital of Harvard University, Massachusetts General Hospital, Boston, Mass. Search for other works by this author on: Oxford Academic PubMed Google Scholar Edgar B. Taft, M.D. Edgar B. Taft, M.D. The Medical Laboratories of the Collis P. Huntington Memorial Hospital of Harvard University, Massachusetts General Hospital, Boston, Mass. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 15, Issue Supplement_5, April 1955, Pages 1591–1593, https://doi.org/10.1093/jnci/15.Supplement_5.1591 Published: 01 April 1955
PNR-30EFFECTIVITY OF TWO DIFFERENT RADIATION-AVOIDING TREATMENT REGIMENS FOR YOUNG CHILDREN WITH PINEOBLASTOMA—RESULTS OF THE HIT2000 TRIAL
Authors: Björn-Ole Juhnke, Martin Mynarek, André O. von Bueren, Carsten Friedrich, Nicolas U. Gerber, Rolf-Dieter Kortmann, Torsten Pietsch, Monika Warmuth-Metz, Katja von Hoff, Stefan Rutkowski
Journal: Neuro-Oncology (2016)
Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-Naïve Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Authors: Susan O'Brien, Nicole Lamanna, Thomas J. Kipps, Ian W. Flinn, Andrew D. Zelenetz, Jan A. Burger, Leanne M. Holes, Yoonjin Cho, Ronald L. Dubowy, Steven E. Coutre
Journal: Blood (2014)
The Biology Complicated by Genetic Analysis
Authors: Xionglei He
Journal: Molecular Biology and Evolution (2016)

Genetics is used as a tool to study living systems because of a key assumption that the phenotypes of loss-of-function mutations on a gene indicate the gene’s normal/native functions. I propose that inactivation of a gene not only suppresses the gene’s native functions but may also create spurious functions that cause phenotypes irrelevant to the gene’s native functions. Such spurious functions represent the otherwise dormant physical/chemical potentials of a living system, do not follow the existing rules built by natural selection, and can hardly be integrated with other functions using empirical data. Thus, the rationale of using loss-of-function phenotypic data to understand a living system is challenged. Fortunately, spurious functions are expected to be evolutionarily unstable while native functions should be conserved, suggesting a means of separating them. I argue that current biology is confused by the undiscerned use of genetic data and suggest a solution.
Redundant Gs-coupled serotonin receptors regulate amyloid-β metabolism in vivo
Authors: Jonathan R. Fisher, Clare E. Wallace, Danielle L. Tripoli, Yvette I. Sheline, John R. Cirrito
Journal: Molecular Neurodegeneration (2016)

The aggregation of amyloid-β (Aβ) into insoluble plaques is a hallmark pathology of Alzheimer's disease (AD). Previous work has shown increasing serotonin levels with selective serotonin re-uptake inhibitor (SSRI) compounds reduces Aβ in the brain interstitial fluid (ISF) in a mouse model of AD and in the cerebrospinal fluid of humans. We investigated which serotonin receptor (5-HTR) subtypes and downstream effectors were responsible for this reduction. Agonists of 5-HT4R, 5-HT6R, and 5-HT7R significantly reduced ISF Aβ, but agonists of other receptor subtypes did not. Additionally, inhibition of Protein Kinase A (PKA) blocked the effects of citalopram, an SSRI, on ISF Aβ levels. Serotonin signaling does not appear to change gene expression to reduce Aβ levels in acute timeframes, but likely acts within the cytoplasm to increase α-secretase enzymatic activity. Broad pharmacological inhibition of putative α-secretases increased ISF Aβ and blocked the effects of citalopram. In total, these studies map the major signaling components linking serotonin receptors to suppression of brain ISF Aβ. These results suggest the reduction in ISF Aβ is mediated by a select group of 5-HTRs and open future avenues for targeted therapy of AD.
High prevalence of T-cell receptor V delta 2-(D)-D delta 3 or D delta 1/2-D delta 3 rearrangements in B-precursor acute lymphoblastic leukemias
Authors: A Biondi, P Francia di Celle, V Rossi, G Casorati, G Matullo, G Giudici, R Foa, N Migone
Journal: Blood (1990)
Diagnosis of intraperitoneal urine leak in a patient with obstructive hydronephrosis using dynamic renal scintigraphy and radionuclide antegrade pyelography.
Authors: S T Lim, M H Sohn, J Y Kwak, C Y Yim
Journal: Clinical Nuclear Medicine (2001)

TAE LIM, SEOK M.D.,*; SOHN, MYUNG-HEE M.D.,*‡; KWAK, JAE-YONG M.D.†‡; YIM, CHANG-YEOL M.D.†‡ Author Information
Inhibition of Sea-Urchin Egg Cleavage by a Series of Substituted Carbamates
Authors: Ivor Cornman
Journal: JNCI Journal of the National Cancer Institute (1950)

Journal Article Inhibition of Sea-Urchin Egg Cleavage by a Series of Substituted Carbamates Get access Ivor Cornman Ivor Cornman Division of Experimental Chemotherapy, Sloan-Kettering Institute for Cancer Research, Bermuda Biological Station, Bermuda, and Lerner Marine Laboratory, Bimini, Bahamas Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 10, Issue 5, April 1950, Pages 1123–1138, https://doi.org/10.1093/jnci/10.5.1123 Published: 01 April 1950 Article history Received: 22 December 1949 Published: 01 April 1950
NU-12THE USE OF AROMATHERAPY TO REDUCE CHEMOTHERAPY-INDUCED NAUSEA IN CHILDREN WITH CANCER; A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL
Authors: Anna Evans, Cassie Garretson, Eliza Pedroja, Jemily Malvar, Ashley Margol, Richard Sposto, Mary Baron Nelson
Journal: Neuro-Oncology (2016)
PTPS-21MAPK PATHWAY INHIBITOR THERAPY FOR PROGRESSIVE PEDIATRIC ASTROCYTOMAS
Authors: Catherine Miller, Christopher Moertel, Daniel Guillaume
Journal: Neuro-Oncology (2015)

BACKGROUND: Brain tumors are the most common solid tumor in childhood and astrocytomas account for the largest proportion of these tumors. Increasing sophistication in genetic testing has allowed for the detection of specific mutations within tumor subtypes that may represent targets for individualized tumor treatment. The MAPK pathway, and more specifically, BRAF mutations have been shown to be prevalent in pediatric astrocytomas and may represent one such area to target. METHODS: We describe the clinical course of four cases of non-operable pediatric astrocytomas (Grade I or II) whose tumor progressed despite chemotherapy. Testing of each tumor showed BRAF mutations and each patient was started on either a BRAF inhibitor or MEK inhibitor. A review of each patient's medical record and imaging studies was completed. Tumor volumetrics were calculated prior to and after treatment. RESULTS: Three patients had optic pathway gliomas; two pilocytic astrocytomas (WHO Grade I) and one pilomyxoid astrocytoma (WHO Grade II). The fourth tumor was a thalamic infiltrating astrocytoma (WHO Grade II). Genetic testing showed a duplication of BRAF (7q34) in 3 tumors and treatment with a MEK inhibitor, trametinib, was initiated. One tumor was found to have a BRAF T1799A (V600E) point mutation and the patient was started on vemurafenib, a BRAF inhibitor. Duration of treatment to date ranged from 105 to 805 days. Pretreatment tumor volumes varied from 15.1cm3-451.8cm3. All four tumors had a decrease in volume (2.1cm3-227.2cm3, 13.5-80.6% decrease) on these inhibitors. CONCLUSION: We have shown in this small subgroup of patients that MEK inhibitors and BRAF inhibitors in tumors with BRAF mutations are effective in decreasing tumor volume in otherwise progressive pediatric astrocytomas. This would suggest these may be ideal targets for treatment of tumors with these mutations and that tumor volume measurement is a reasonable method for documenting response in this patient group.
Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
Authors: Claudia Bracaglia, Kathy de Graaf, Denise Pires Marafon, Florence Guilhot, Walter Ferlin, Giusi Prencipe, Ivan Caiello, Sergio Davì, Grant Schulert, Angelo Ravelli, Alexei A Grom, Cristina de Min, Fabrizio De Benedetti
Journal: Annals of the Rheumatic Diseases (2016)

Objectives Interferon-γ (IFNγ) is the pivotal mediator in murine models of primary haemophagocytic lymphohistiocytosis (pHLH). Given the similarities between primary and secondary HLH (sec-HLH), including macrophage activation syndrome (MAS), we investigate the involvement of the IFNγ pathway in MAS by evaluating levels of IFNγ and of the induced chemokines, and their relation with laboratory parameters of MAS in systemic juvenile idiopathic arthritis (sJIA) patients with MAS and in a murine MAS model. Methods The Luminex multiplexing assay was used to assess serum levels of interleukin (IL)-1β, IL-6, IFNγ and of the IFNγ-induced chemokines CXCL9, CXCL10 and CXCL11 in patients with sec-HLH (n=11) and in patients with sJIA (n=54), of whom 20 had active MAS at sampling. Expression of IFNγ-induced chemokines was assessed in IL-6 transgenic mice in which MAS is induced by TLR4 stimulation with lipopolysaccharide. Results Levels of IFNγ and of IFNγ-induced chemokines were markedly elevated during active MAS and sec-HLH and were significantly higher in patients with MAS compared with active sJIA without MAS. Levels in patients with active sJIA without MAS were comparable to those of patients with clinically inactive sJIA. During MAS, ferritin and alanine transferase levels and neutrophil and platelet counts were significantly correlated with serum levels of IFNγ and CXCL9. In murine MAS, serum levels of ferritin were significantly correlated with mRNA levels of Cxcl9 in liver and spleen. Conclusions The high levels of IFNγ and of IFNγ-induced chemokines and their correlation with the severity of laboratory abnormalities of MAS suggest a pivotal role of IFNγ in MAS.